Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Apolipoprotein E genotype is not associated with cognitive impairment in older adults with bipolar disorder

Texto completo
Autor(es):
Kerr, Daniel Shikanai [1, 2] ; Stella, Florindo [1, 3] ; Radanovic, Marcia [1] ; Aprahamian, Ivan [1] ; Ferreira Bertollucci, Paulo Henrique [4] ; Forlenza, Orestes Vicente [1, 2]
Número total de Autores: 6
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Fac Med, Dept & Inst Psychiat, Lab Neurosci LIM 27, Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Ctr Interdisciplinary Res Appl Neurosci NAPNA, Sao Paulo, SP - Brazil
[3] Univ Estadual Paulista, UNESP, Biosci Inst, Sao Paulo, SP - Brazil
[4] Univ Fed Sao Paulo, UNIFESP, Dept Neurol & Neurosurg, Sao Paulo, SP - Brazil
Número total de Afiliações: 4
Tipo de documento: Artigo Científico
Fonte: BIPOLAR DISORDERS; v. 18, n. 1, p. 71-77, FEB 2016.
Citações Web of Science: 5
Resumo

ObjectivesCognitive decline is part of the long-term outcome for many individuals with bipolar disorder (BD). The epsilon 4 allele (APOE{*}4) of apolipoprotein E (APOE) is a well-established risk factor for dementia in Alzheimer's disease (AD). However, its contribution to the risk of cognitive deterioration in BD has not yet been determined. Our aim was to analyze the APOE genotype association with cognitive status in a sample of older adults with BD and compare this to the association in individuals with AD, individuals with mild cognitive impairment (MCI), and healthy controls. MethodsParticipants (n=475) were allocated to four groups: individuals with BD (n=77), those with AD (n=211), those with MCI (n=43), and healthy controls (n=144) according to clinical and neuropsychological assessment. APOE was genotyped by real-time polymerase chain reaction. Tukey's honest significant difference test and Pearson's chi-squared test were used to compare diagnostic groups. ResultsSubjects with BD were similar to controls with respect to the distribution of the APOE genotype (p=0.636) and allele frequencies (p=0.481). Significant differences were found when comparing the AD group to the BD group or to controls (APOE genotype: p<0.0002; allele frequencies: p<0.001). APOE{*}4 was significantly increased in the AD group when compared to the BD group (p=0.031) and controls (p<0.0001). The cognitively impaired BD subgroup (Mini-Mental State Examination below the cutoff score and/or neuropsychological assessment compatible with MCI) had a statistically significant higher frequency of APOE{*}2 compared to the AD group (p=0.003). ConclusionsAPOE{*}4 is not associated with the diagnosis of BD and does not impact the occurrence of dementia in BD. Given the distinct clinical and biological features of cognitive impairment in BD, we hypothesized that dementia in BD is unrelated to AD pathological mechanisms. (AU)

Processo FAPESP: 13/01352-8 - Efeito do lítio na regulação da expressão gênica por micro RNAs em modelo da Doença de Alzheimer por toxicidade de beta-amilóide em cultura primária de neurônios
Beneficiário:Daniel Shikanai Kerr
Modalidade de apoio: Auxílio à Pesquisa - Regular
Processo FAPESP: 09/52825-8 - Neurobiologia da doença de Alzheimer: marcadores de risco, prognóstico e resposta terapêutica
Beneficiário:Wagner Farid Gattaz
Modalidade de apoio: Auxílio à Pesquisa - Temático